What Happens to a Clinical Trial Site That Consistently Misses Enrollment Targets

A clinical trial site that consistently misses enrollment targets faces consequences that compound over time. The first consequence is immediate: the underperforming site may be removed from the active study and the enrollment target redistributed to other sites. The second consequence is longer-term: a poor enrollment track record is documented in CRO databases and used in future site selection decisions. The third consequence is the most damaging: reduced study volume limits the revenue available to invest in the operational improvements that would prevent future enrollment failure.

What Happens Within the Current Study

CROs monitor enrollment velocity on a weekly basis for active studies. Sites that are tracking significantly below their projected enrollment rate receive performance calls from the CRO's clinical operations team, then a formal performance improvement discussion, then — if the trajectory does not improve — a formal decision about whether to continue site activation or reallocate the enrollment target to a better-performing site.

Site removal from an active study is not rare. It is a documented and standard practice that CROs use to protect study timelines when a site demonstrates it cannot deliver what it projected in feasibility. The site loses the remaining per-patient revenue for the study. The sponsor redirects the enrollment target. The study timeline is preserved at the site's expense.

What Happens to Future Study Acquisition

CROs maintain performance records for every site they have worked with. A site that was removed from a study, or that completed a study at 30 percent of its projected enrollment, enters the next feasibility evaluation with that history visible. The site's feasibility projections are discounted. Its selection probability for competitive indications decreases. Over several studies, a pattern of enrollment underperformance becomes effectively disqualifying for complex, high-value studies.

The Compounding Effect

Reduced study volume from poor enrollment track record reduces per-study revenue. Reduced revenue limits the ability to hire additional coordinator staff or invest in enrollment infrastructure. Limited coordinator capacity and infrastructure makes future enrollment more difficult. This is the compounding cycle that underperforming sites must break — and the only way to break it is to invest in operational infrastructure before the next study, not after the performance problem has already appeared.